Unknown

Dataset Information

0

Cannabis-Based Oral Emulsion for Medical Purposes to Meet the Needs of Patients: Formulation, Quality and Stability.


ABSTRACT: Current Italian legislation provides that medical Cannabis can be administered orally as an extract if it has been titrated to determine the concentration of active molecules. In this context, there is a need to provide known and adequate quantities of active ingredients in order to guarantee uniform therapies that lead to the optimization of risks/benefits. This is fundamental considering that the limited availability on the market of registered Cannabis-based products for medical use means that prescribed therapies are usually prepared as galenic preparations. Consequently, the preparation procedures must be consistent with the instrumentation usually present in the laboratories of community pharmacies. In this context, the purpose of this work was to standardize the preparation procedure for oil-in-water (O/W) emulsions to exploit advantages in terms of ease of administration and dosage adjustment, but also to ensure the palatable organoleptic characteristics of the finished product. For the formulations being studied, in addition to the quality according to the directives set out in the European Pharmacopoeia, the stability was evaluated to assure adequate validity for therapeutic uses.

SUBMITTER: Baratta F 

PROVIDER: S-EPMC8954602 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

<i>Cannabis</i>-Based Oral Emulsion for Medical Purposes to Meet the Needs of Patients: Formulation, Quality and Stability.

Baratta Francesca F   Peira Elena E   Maza Carola C   Gallarate Marina M   Brusa Paola P  

Pharmaceutics 20220225 3


Current Italian legislation provides that medical <i>Cannabis</i> can be administered orally as an extract if it has been titrated to determine the concentration of active molecules. In this context, there is a need to provide known and adequate quantities of active ingredients in order to guarantee uniform therapies that lead to the optimization of risks/benefits. This is fundamental considering that the limited availability on the market of registered <i>Cannabis</i>-based products for medical  ...[more]

Similar Datasets

| S-EPMC10251568 | biostudies-literature
| S-EPMC7066509 | biostudies-literature
| S-EPMC6699531 | biostudies-literature
| S-EPMC7671185 | biostudies-literature
| S-EPMC11003000 | biostudies-literature
| S-EPMC9110511 | biostudies-literature
| S-EPMC6514948 | biostudies-literature
| S-EPMC6225592 | biostudies-literature
| S-EPMC8820604 | biostudies-literature